Discontinued — last reported Q4 '25
Business Segments · Acquisitions
Pharmaceuticalsegment — Acquisitions
Over 2 years (FY 2021 to FY 2025), Pharmaceuticalsegment — Acquisitions shows a downward trend with a -100.0% CAGR.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityVolatile
First reportedQ1 2014
Last reportedQ4 2025
How to read this metric
Higher spending indicates an aggressive growth strategy, while zero spending suggests a focus on organic development or capital preservation.
Detailed definition
Captures the cash outflow or accounting value associated with purchasing other companies or product lines to expand the...
Peer comparison
Highly variable across the industry depending on the current M&A cycle and patent cliff exposure.
Metric ID:
mrk_segment_pharmaceutical_segment_acquisitionsHistorical Data
3 years
| FY'21 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $2.43B | $0.00 | $0.00 |
| YoY Change | — | -100.0% | — |
Range$0.00 – $2.43B
CAGR-100.0%
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s pharmaceuticalsegment — acquisitions?
- Merck & Co. (MRK) reported pharmaceuticalsegment — acquisitions of $0.00 in Q4 2025.
- What is the long-term trend for Merck & Co.'s pharmaceuticalsegment — acquisitions?
- Over 2 years (2021 to 2025), Merck & Co.'s pharmaceuticalsegment — acquisitions has grown at a -100.0% compound annual growth rate (CAGR), from $2.43B to $0.00.
- What does pharmaceuticalsegment — acquisitions mean?
- The total cost incurred to acquire other businesses or assets within the pharmaceutical segment.